
==== Front
J Cardiothorac Surg
J Cardiothorac Surg
Journal of Cardiothoracic Surgery
1749-8090
BioMed Central London

39272103
3032
10.1186/s13019-024-03032-y
Research
Clinical significance of postoperative thrombocytosis after vats lobectomy for NSCLC
Leonardi Beatrice beatrice.leonardi@unicampania.it

1
Natale Giovanni 1
Ferraioli Salvatore 1
Leone Francesco 1
Grande Mario 1
Puca Maria Antonietta 1
Rainone Anna 1
Messina Gaetana 1
Sica Antonello 2
Fiorelli Alfonso 1
1 grid.9841.4 0000 0001 2200 8888 Thoracic Surgery Unit, University of Campania “Luigi Vanvitelli” Università degli Studi della Campania “Luigi Vanvitelli”, Via Pansini, 5, Naples, I-80138 Italy
2 https://ror.org/02kqnpp86 grid.9841.4 0000 0001 2200 8888 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, 80138 Italy
14 9 2024
14 9 2024
2024
19 5291 6 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Objectives

Thrombocytosis is a clinical condition generally associated with poor prognosis in patients with cancer. Thrombocytosis may be present after lung cancer resection, but the clinical significance of thrombocytosis remains unclear. Herein, we evaluated whether postoperative thrombocytosis was a negative prognostic factor in patients undergoing thoracoscopic lobectomy for lung cancer.

Methods

It was a retrospective monocentric study including consecutive patients undergoing thoracoscopic lobectomy for lung cancer from January 2020 to January 2023. The outcome of patients with postoperative thrombocytosis (defined as platelet count ≥ 450 × 10^9/L at 24 h after the surgery and confirmed at postoperative day 7) was compared with a control group. Postoperative morbidity, mortality, and survival were compared between the two groups to define whether thrombocytosis negatively affected outcomes.

Results

Our study population included 183 patients; of these, 22 (12%) presented postoperative thrombocytosis: 9 (5%) mild thrombocytosis (451–700 × 10^9/L), 10 (5%) moderate thrombocytosis (701–900 × 10^9/L), and 3 (2%) severe thrombocytosis (901–1000 × 10^9/L). No significant differences were found regarding postoperative morbidity (p = 0.92), mortality (p = 0.53), overall survival (p = 0.45), and disease-free survival (p = 0.60) between the two study groups. Thrombocytosis was associated with higher rate of atelectasis (36% vs. 6%, p < 0.001) and residual pleural effusion (31% vs. 8%, p = 0.0008). Thrombocytosis group was administered low-dose acetylsalicylic acid for 10 days and no thrombotic events were observed. In all cases the platelet count returned to be within normal value at postoperative day 30.

Conclusions

Postoperative thrombocytosis seems to be a transient condition due to an inflammatory state and it does not affect the surgical outcome and survival after thoracoscopic lobectomy.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13019-024-03032-y.

Keywords

Lobectomy
Thrombocytosis
Lung cancer
Thoracoscopy
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Lung cancer is the most common cancer and the leading cause of cancer deaths worldwide [1, 2]. Non-small-cell lung cancer (NSCLC) accounts for 80% of all cases. Surgical resection remains the only treatment with curative intent for early-stage lung cancer [3].

Many studies have shown that thrombocytosis, defined as platelet count ≥ 450 × 10^9/L, plays a role in cancer genesis and development. Increasing evidence has indicated that platelet count correlates with prognosis in various malignancies, such as lung, renal, gastric, colorectal, and hepatocellular cancer and pre-treatment thrombocytosis is considered a poor prognostic factor in NSCLC [4, 5]. Thrombocytosis may be occasionally observed in patients undergoing lung cancer resection with normal pre-operative platelet count, but its clinical significance and management remains unclear. Given the undefined role of postoperative thrombocytosis in patients with NSCLC, a focus on this specific clinical condition could help the physician understand if the patient is undergoing a para-physiological condition or if concern regarding the oncological prognosis should be raised.

Herein, we evaluated whether postoperative thrombocytosis after video-assisted thoracoscopic (VATS) lobectomy affects the surgical outcome and/or prognosis in patients undergoing surgical resection for NSCLC.

Materials and methods

Study design

This was a retrospective monocentric study conducted at the Thoracic Surgery Unit of Campania “Vanvitelli”, Naples, Italy. The clinical data of consecutive patients undergoing lobectomy for lung cancer from January 2020 to January 2023 were evaluated. The data of patients (i) undergoing lobectomy for lung cancer; (ii) with complete data and (iii) with follow-up for at least 3 months were included in the analysis. We excluded the data of patients: (i) undergoing lung resection different from lobectomy (i.e. wedge resection, segmentectomy, bilobectomy and pneumonectomy); (ii) with incomplete pre and postoperative data, to minimize the amount of missing data; and (iii) with pre-existing haematological conditions. Patients undergoing resection different from lobectomy were excluded to have a homogeneous sample, as a more extended resection could be associated with different surgical and oncological outcomes, as well as a sub-lobar resection. Furthermore, pre-existing haematological conditions could constitute a confounding factor to assess any association between postoperative thrombocytosis and surgical/oncological variables. The CONSORT flow diagram showing the process of assessing the eligibility is reported in Fig. 1.

Fig. 1 CONSORT flow diagram of the study

The patients were divided in two groups based on whether they had postoperative thrombocytosis (Thrombocytosis group), or not (Control group). The inter group differences regarding postoperative morbidity, mortality and survival were statistically compared to define whether thrombocytosis negatively affected outcomes and survival (endpoints of the study).

The Institutional Review Boards of the University of Campania “Luigi Vanvitelli” waived the need for ethical approval due to the retrospective nature of the study since there was no modification to the standard of care for the patients. In all cases, informed written consent was obtained from the patients for the treatment and for the anonymous use and publication of their data for scientific purposes. All procedures were performed in accordance with international guidelines; with the Helsinki Declaration of 1975, revised in 1983; and the rules of the Italian laws of privacy.

Study population

We recorded the following data for each patient: age, sex, symptoms, comorbidities, respiratory function data, histology and tumor stage based on 8th edition of TNM stage. Operative time (minutes), blood loss (mL), chest drainage output (mL), length of chest drainage (days), length of hospital stay (LHOS, days), laboratory data, postoperative complications, 90-day mortality were also recorded. Recurrence and time of recurrence were recorded. Overall survival (OS) and disease-free survival (DFS) were also measured from the date of surgery until death or recurrence, respectively.

Blood markers

Thrombocytosis was defined as platelet count ≥ 450 × 10^9/L first detected with routine blood test 24 h after the surgery and confirmed at postoperative day 7. Thrombocytosis was classified in mild (451–700 × 10^9/L), moderate (701–900 × 10^9/L), severe (901–1000 × 10^9/L) or extreme (> 1000 × 10^9/L), following a classification previously adopted in literature [6]. Additionally, we evaluated the following blood inflammatory biomarkers: neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR), systemic pan-immune-inflammation index (SII) [7–10].

In patients with post-operative thrombocytosis, platelet count and the other inflammatory markers were evaluated weekly until 30 post-operative day.

Surgical procedure

All the patients underwent pulmonary lobectomy with systematic ilo-mediastinal lymphadenectomy through a standard anterior thoracoscopic triportal approach. The procedures were carried out under general anaesthesia with selective intubation. A single 28Fr drainage tube was placed in the pleural cavity at the end of the procedure and removed when the amount of fluid drained was less than 250 mL in 24 h, in absence of air leaks.

Statistical analysis

Data were expressed as mean ± Standard Deviation (SD) for continuous variables and as absolute number and percentage for categorical variables. Differences between groups were evaluated using Chi-squared test for categorical variables and with Student´s T-test for continuous variables. The correlation between thrombocytosis and the other inflammatory markers were calculated by Pearson correlation coefficient. The OS and DFS were evaluated by Kaplan-Meier method and the log-rank test was used to calculate the difference between two study groups. Univariable and multivariable analysis were used to identify independent risk factors for postoperative complications (dependent variable). A p-value less than 0.05 was considered statistically significant. MedCalc statistical software (Version 12.3, Broekstraat 52; Mariakerke, Belgium) was used for this analysis.

Results

During the study period, 235 patients underwent lung resection for NSCLC. Out of these, 52 patients were excluded from the study due to resections different from lobectomy (n = 49), and missing data (n = 3). Thus, our study population included 183 patients; of these, 22 (12%) presented postoperative thrombocytosis: 9 (5%) mild, 10 (5%) moderate, and 3 (2%) severe thrombocytosis (Table 1). There were no cases of extreme thrombocytosis.

Table 1 Characteristics of study population

Variables	Total	Thrombocytosis	Control group	p-Value	
(n = 183)	group	(n = 161)	
	(n = 22)		
Age (years), M ± SD	66.7 ± 8.3	65.2 ± 8.2	66.9 ± 8.4	0.19	
Gender (male), n (%)	106 (58)	15 (68)	91 (56)	0.29	
Smokers, n (%)	83 (45)	13 (59)	70 (44)	0.16	
Former smokers, n (%)	71 (39)	6 (27)	65 (40)	0.23	
BMI (Kg/m2), M ± SD	27.2 ± 4.3	26.5 ± 3.8	27.4 ± 4.3	0.11	
ASA score ≥ 3	65 (35)	7 (31)	58 (36)	0.32	
Comorbidities, n (%)					
 Diabetes	34 (19)	2 (9)	32 (20)	0.22	
 COPD	53 (29)	8 (36)	45 (28)	0.41	
 Hypertension	130 (71)	17 (77)	113 (70)	0.49	
 Coronary artery disease	32 (17)	3 (14)	29 (18)	0.61	
 History of cancer	59 (32)	4 (18)	55 (34)	0.13	
Preoperative FEV1%, M ± SD	94.1 ± 18	89.9 ± 12	94.6 ± 20	0.14	
Preoperative DLCO%, M ± SD	87.3 ± 19	88.9 ± 20	87.0 ± 18.6	0.36	
Mild thrombocytosis, n (%)	9 (5)	9 (41)	0	/	
Moderate thrombocytosis, n (%)	10 (5)	10 (45)	0	/	
Severe thrombocytosis, n (%)	3 (2)	3 (14)	0	/	
Histology, n (%)					
 Adenocarcinoma	120 (65)	12 (54)	108 (67)	0.24	
 Squamous cell carcinoma	35 (19)	7 (32)	28 (17)	0.1	
 Typical carcinoid	6 (4)	1 (5)	5 (3)	0.72	
 Atypical carcinoid	6 (4)	0	6 (4)	0.85	
 Other	16 (8)	2 (9)	14 (9)	0.95	
Lobectomy type, n (%)					
 RUL	58 (32)	8 (36)	50 (31)	0.61	
 RML	13 (7)	0	13 (8)	0.55	
 RLL	40 (22)	6 (27)	34 (21)	0.51	
 LUL	34 (18)	6 (27)	28 (17)	0.26	
 LLL	38 (21)	2 (9)	36 (22)	0.19	
Pathological stage, n (%)					
 IA	78 (43)	11 (50)	67 (42)	0.45	
 IB	29 (16)	3 (14)	26 (16)	0.76	
 IIA	5 (3)	1 (5)	4 (2)	0.57	
 IIB	22 (12)	4 (18)	18 (11)	0.34	
 IIIA	23 (13)	2 (9)	21 (13)	0.59	
BMI: body mass index. ASA: American Society of Anesthesiologists. COPD: chronic obstructive pulmonary disease. FEV1: forced expiratory volume in 1 s. DLCO: diffusing capacity of the lung for carbon monoxide. RUL: right upper lobectomy. RML: right middle lobectomy. RLL: right lower lobectomy. LUL: left upper lobectomy. LLL: left lower lobectomy

No significant differences were found between two study groups regarding pre-operative data, histology, and tumor stage, as summarized in Table 1.

Surgical outcome

Perioperative outcomes were summarized in Table 2. Operative time (p = 0.56), blood loss (p = 0.41), transfusion rate (p = 0.7), conversion rate (p = 0.73), chest drainage output (p = 0.25), length of chest drainage (p = 0.35) and LHOS (p = 0.32) were similar between two study groups without significant difference.

Table 2 Surgical outcome comparison

Variables	Total
(n = 183)	Thrombocytosis group
(n = 22)	Control group
(n = 161)	p-value	
Operative time (minutes), M ± SD	169 ± 46	166 ± 43	170 ± 47	0.35	
Chest drainage (mL/day), M ± SD	142 ± 60	146 ± 63	140 ± 70	0.25	
Chest tube duration (days), M ± SD	6 ± 4	6 ± 4	5 ± 4	0.35	
Blood loss (mL), M ± SD	282 ± 55	280 ± 50	285 ± 61	0.41	
Transfusion, n (%)	21 (11)	2 (9)	19 (11)	0.70	
Conversion, n (%)	20 (10)	2 (9)	18 (10)	0.73	
LHOS (days), M ± SD	7.2 ± 4.0	7.6 ± 3.5	6.8 ± 3.4	0.32	
Complications, n (%):

Patients with any complication

Minor complications (grade I-II*)

Major complications (grade III-IV*)

	65 (35)

51 (28)

14 (7)

	8 (36)

7 (32)

1 (5)

	57 (35)

44 (27)

13 (8)

	0.92

0.65

0.55

	
Bronchoscopy for atelectasis, n (%)	18 (10)	8 (36)	10 (6)	< 0.001	
Residual pleural effusion, n (%)	20 (11)	7 (31)	13 (8)	0.00081	
90 – day mortality, n (%)	3 (2)	0	3 (2)	0.53	
OS (months), M ± SD	14 ± 11	15 ± 4	14.5 ± 5	0.45	
DFS (months), M ± SD	13 ± 10	15 ± 11	13 ± 10	0.60	
LHOS: Length of hospital stay. OS: Overall survival. DFS: Disease free survival

*According to the Systematic Classification of Morbidity and Mortality After Thoracic Surgery (Seely AJE et al.)

Thrombocytosis compared to control group was associated with a higher rate of residual pleural effusion (31% vs. 8%, p = 0.0008), and atelectasis that needed bronchoscopic aspiration (36% vs. 6%, p < 0.001). However, no significant difference was found regarding the overall complications rate between two study groups. Multivariable analysis showed that only COPD was an independent prognostic factor for complications (Table 3).

Table 3 Univariable and multivariable analysis for peri-operative complications (dependent variable)

Variables	Univariable	Multivariable	
Odds Ratio	p-value	Odds Ratio	p-value	
Age (> 70)	0.96 (CI: 0.90–1.02)	0.20	-	-	
Gender	0.70 (CI: 0.23–2.10)	0.53	-	-	
Smoking status	0.87 (CI: 0.29–2.63)	0.81	-	-	
COPD	3.02 (CI: 1.00-9.12)	0.049*	3.40 (CI 1.52–8.35)	0.022	
Diabetes	1.21 (CI: 0.31–4.61)	0.77	-	-	
Thrombocytosis	0.54 (CI 0.06–4.35)	0.53	-	-	
ASA ≥ 3	0.70 (CI: 0.21–2.35)	0.56	-	-	
FEV1 < 70%	1.24 (CI 0.25–5.95)	0.79	-	-	
History of cancer	1.12 (CI: 0.35–3.50)	0.84	-	-	
COPD: chronic obstructive pulmonary disease. ASA: American Society of Anesthesiologists. CI: confidence interval

Correlation between thrombocytosis and other inflammatory markers

Preoperative and postoperative laboratory data were reported in Table 4. Thrombocytosis group compared to control group presented higher value of SII (2155 ± 1244 vs. 643 ± 200, p = 0.0004); of PLR (312 ± 139 vs. 134 ± 64, p = 0.0028); of NLR (4.6 ± 1.2 vs. 2.6 ± 0.8; p = 0.93), and lower value of LMR (3.4 ± 1.1vs. 5.8 ± 0.5; p = 0.000046). Additionally, Pearson correlation coefficient (Fig. 2) found a moderate positive correlation between platelet count and SII (r(181) = 0.50, p = 0.0001, Fig. 2/A); a positive correlation between platelet count and PLR (r(181) = 0.22, p = 0.002, Fig. 2/B); a moderate positive correlation between platelet count and NLR (r (181) = 0.46, p < 0.0001, Fig. 2/C), and a negative correlation between platelet count and LMR (r (181) = -0.23, p = 0.0014, Fig. 2/D).

Table 4 Laboratory data and inflammatory biomarkers

Variables	Total
(n = 183)	Thrombocytosis
(n = 22)	No thrombocytosis
(n = 161)	p-Value	
Preoperative laboratory data, (M ± SD):

 • White blood cells (/uL)

 • Hemoglobin (g/dL)

 • Platelet count (x10^3/uL)

 • Total protein (g/dL)

	7750 ± 2238

13.96 ± 1.8

241 ± 58

6.9 ± 0.71

	8020 ± 2711

13.1 ± 2.2

297 ± 108

6.8 ± 0.65

	7720 ± 2173

13.9 ± 1.8

232 ± 59

7 ± 0.71

	0.15

0.18

0.000017

0.45

	
Postoperative laboratory data (day 7), (M ± SD):

 • White blood cells (/uL)

 • Hemoglobin (g/dL)

 • Platelet count (x10^3/uL)

 • Total protein (g/dL)

	8720 ± 2200

11.9 ± 1.7

300 ± 179

6.8 ± 0.81

	1050 ± 2033

10.8 ± 1.3

690 ± 153

6.6 ± 0.75

	8200 ± 1500

11.7 ± 1.5

250 ± 72

6.9 ± 0.53

	0.17

0.34

< 0.00001

0.82

	
SII, (cutoff < 1266) (M ± SD)	763 ± 502	2155 ± 1244	643 ± 200	0.0004	
PLR, (cutoff < 200) (M ± SD)	156 ± 89	312 ± 139	134 ± 64	0.0028	
NLR, (cutoff < 4) (M ± SD)	2.8 ± 1.7	4.6 ± 1.2	2.6 ± 0.8	0.93	
LMR, (cutoff ≥ 4) (M ± SD)	5.5 ± 2.4	3.4 ± 1.1	5.8 ± 2.4	0.000046	
Postoperative day 30 data, (M ± SD):	
Platelet count (x10^3/uL)	/	350 ± 62	/	/	
SII, (cutoff < 1266) (M ± SD)	/	710 ± 97	/	/	
PLR, (cutoff < 200) (M ± SD)	/	152 ± 34	/	/	
NLR, (cutoff < 4) (M ± SD)	/	2.86 ± 0.9	/	/	
LMR, (cutoff ≥ 4) (M ± SD)	/	5.75 ± 2.13	/	/	
SII: systemic pan-immune-inflammation index. PLR: platelet/lymphocyte ratio. NLR: neutrophil/lymphocyte ratio. LMR: lymphocyte/monocyte ratio

Fig. 2 Pearson Correlation coefficient between thrombocytosis and inflammatory biomarkers. (A): Moderate positive correlation between platelet count and SII (r(181) = 0.50, p = 0.0001); (B): Positive correlation between platelet count and PLR (r(181) = 0.22, p = 0.002); (C): Moderate positive correlation between platelet count and NLR (r (181) = 0.46, p < 0.0001); (D): Negative correlation between platelet count and LMR (r (181) = -0.23, p = 0.0014) LMR

All the patients with thrombocytosis received weekly hematologic evaluation and were treated with low-dose acetylsalicylic acid. In all cases the platelet count (Supplementary Fig. 1) and all inflammatory markers (Fig. 3) returned to be within normal values at postoperative day 30. No thrombotic events or other complications were observed during the follow-up.

Fig. 3 Inflammatory biomarkers distribution in Thrombocytosis group at 1 and 30 postoperative days. (A): SII; (B): PLR; (C): NLR; (D): LMR

Recurrence and survival

The median follow-up was 15 months. Overall survival (p = 0.45), disease-free survival (p = 0.60) and 90-day mortality (p = 0.53) were similar between the two groups. Kaplan-Meier survival curves are reported in Fig. 4. Log-rank test showed no significant difference between the two groups regarding overall survival (p = 0.35) and disease-free survival (p = 0.15) Fig. 4.

Fig. 4 Kaplan-Meier curves. (A): Overall survival; (B): Disease-free survival

Discussion

Thrombocytosis is a poor prognostic factor in neoplastic patients [11]. The association between thrombocytosis and cancer is well defined despite the mechanism remains unclear. A role is attributed to epithelial mesenchymal transformation of tumor cells promoted by platelets through secretion of transforming growth factor-β [12]. On the other hand, some support that a proangiogenic role of activated platelets favours tumor diffusion [13, 14]. Preoperative thrombocytosis is suspected to have a role in metastatic diffusion as activated platelets facilitate hematological diffusion of tumor cells, shielding them from immune destruction. Even though the relation between preoperative thrombocytosis and tumor prognosis is yet not clearly defined, preoperative thrombocytosis is considered a marker of cancer aggressivity.

Nevertheless, thrombocytosis may occur after lung cancer resection, but the clinical significance is still unexplored. Postoperative thrombocytosis has been observed and studied after colorectal oncological surgery [15] and urological surgery [16]. Hemorrhage, urosepsis and thromboembolism were the most common complications recorded in patients with thrombocytosis after urological surgery, while median overall survival resulted worse in patient with thrombocytosis after colorectal surgery. No studies, before the present, evaluated whether postoperative thrombocytosis after lung cancer resection is a poor prognostic factor for surgical outcome and survival.

First, postoperative thrombocytosis did not negatively affect post-operative surgical outcome. No significant differences between the two study groups were found regarding the complications rate. These results were confirmed by multivariable analysis that identified only COPD as an independent prognostic factor for complications. The distribution of COPD was homogeneous between the two study groups, and COPD is known to be a risk factor for postoperative complications in patients undergoing VATS lobectomy for lung cancer [17]. Thus, our data showed no significant association between COPD and thrombocytosis. However, since the small sample size of our study population and the lack of data from literature, we are unable to provide any definitive conclusion about this issue that should be investigated in further studies.

In thrombocytosis group, a significant increase of residual pleural effusion and atelectasis was found compared to control group, requiring more often bronchoscopic aspiration. Pleural effusion has been associated with pleural and local inflammation [18–20], that may be a predisposing factors for thrombocytosis in this cohort of patients. This hypothesis is supported by the significant correlation observed between platelet count and other inflammatory markers in thrombocytosis group. Atelectasis and residual pleural effusion are common complications after VATS lobectomy, which should be addressed to prevent hypoxemia and infections. Breathing exercises, physical therapy, and bronchoscopy, are key elements in the management of these complications. It is important to correlate to clinical signs and general condition to exclude any underlying conditions (e.g. infection, pulmonary embolism, etc.) [21].

Second, postoperative thrombocytosis was not a poor prognostic factor. Indeed, no significant difference in terms of recurrence and overall survival was found between the two study groups. A correlation between pretreatment thrombocytosis and unfavorable lung cancer prognosis has been reported in recent meta- analysis and systematic reviews [1, 22], while some suggest that a high platelet count is not an independent prognostic factor for survival [23, 24]. In fact, thrombocytosis role in lung cancer is yet not clear as the prognostic value of thrombocytosis could not be confirmed by all studies.

In our study, postoperative thrombocytosis was not associated with survival and recurrence. Patients with postoperative thrombocytosis presented a normal preoperative platelet count, therefore platelet formation mechanism could be considered a reactive process. This finding is supported by the parallel inflammatory biomarkers and platelet count normalization at postoperative day 30. We think that the differences between our findings and the studies supporting a negative prognostic value of thrombocytosis in NSCLC resides in the diverse circumstance of thrombocytosis occurrence. Most of the studies that have found an association between thrombocytosis and a worse prognosis refer to preoperative or pre-treatment thrombocytosis [1, 5, 8, 25]. Other studies found a correlation between thrombocytosis and poor survival in cohorts of patients with advanced metastatic NSCLC treated with chemo-immunotherapy [26, 27].

To our knowledge, only a paper from Maràz et al. explicitly included patients with postoperative thrombocytosis [28], reporting that perioperative thrombocytosis in patients undergoing lung cancer surgery should be considered as an independent prognostic factor of poor survival. However, their research is based on the assessment of platelet count higher than 400 × 10^3/uL just before surgery and on postoperative day 1 and 7. One study that analyzed postoperative thrombocytosis in colorectal surgery for cancer [15] found that both preoperative and postoperative thrombocytosis are predictive for worse survival. Nevertheless, postoperative thrombocytosis in this study was measured at postoperative day 30, with the intent of excluding the inflammatory effects of the surgery. In our study, we included only patients with resectable NSCLC and postoperative thrombocytosis, that was in all cases transient, being absent before surgery and with return to normal platelet values within postoperative day 30.

Third, our results highlighted that postoperative transient thrombocytosis is a phenomenon related to an inflammatory reactive condition, that can be easily managed by the physician without influencing the patient recovery after thoracic surgery. Treatment with low-dose acetylsalicylic acid is generally used to prevent thrombotic events in essential thrombocytosis [29, 30], but we considered its use in reactive thrombocytosis with prophylactic intent. Mohamud et al. [31] did not treat postoperative thrombocytosis but observed a higher rate of complications in the thrombocytosis group. In our study, the platelet count returned to normal within 30-day postoperative, along with inflammatory biomarkers descent. The relationship between thrombocytosis and atelectasis/residual pleural effusion should be better investigated, as it could offer some perspective about platelet role in the mechanisms of postoperative recovery and of injury-induced inflammatory response [32, 33].

Thrombocytosis should be differentiated according to its onset and duration: a transient postoperative thrombocytosis is more likely to be an inflammatory phenomenon without significant influence on the patient’s prognosis, while persistent preoperative or pre-treatment thrombocytosis is commonly related to a worse oncological prognosis, as it relates with advanced stages of NSCLC. In the postoperative period, a finding of thrombocytosis should not scare the surgeon with a certainty of a worse prognosis, but it should be considered in the context of the patient’s clinical evolution.

The main limitations of our study were the retrospective nature, the absence of randomization, the small cohort of patients and the relatively short follow-up (median 15 months). For these reasons our findings must be investigated with further larger and prospective studies.

Conclusions

Postoperative thrombocytosis seems to be a transient condition due to an inflammatory state and it does not seem to affect the surgical outcome and survival after thoracoscopic lobectomy for lung cancer. Prophylactic treatment with low-dose acetylsalicylic acid may be considered to prevent thrombotic events. Our preliminary results should be corroborated by larger, prospective studies.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Acknowledgements

None.

Author contributions

Conceptualization: B.L. and A.F. Data curation: B.L. and S.F Methodology: G.N. and F.L; Investigation: M.G and M.A.P., Formal analysis: A.R and F.L. Resources: A.S and A.R. Writing – original draft: B.L. and G.N., Writing – review and editing: A.F., M.G. Visualization: B.L. S.F and A.F. Supervision: G.M.

Funding

This research received no external funding.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

The Institutional Review Boards of the University of Campania “Luigi Vanvitelli” waived the need for ethical approval due to the retrospective nature of the study since there was no modification to the standard of care for the patients. In all cases, informed written consent was obtained from the patients for the treatment and for the anonymous use and publication of their data for scientific purposes. All procedures were performed in accordance with international guidelines; with the Helsinki Declaration of 1975, revised in 1983; and the rules of the Italian laws of privacy.

Consent for publication

All patients signed an informed consent for the anonymous publications of their data for scientific purposes.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Yuan Y Zhong H Ye L Li Q Fang S Gu W Qian Y Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis BMC Pulm Med 2020 20 1 96 10.1186/s12890-020-1139-5 32312252
Yuan Y, Zhong H, Ye L, Li Q, Fang S, Gu W, Qian Y. Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis. BMC Pulm Med. 2020;20(1):96.32312252 10.1186/s12890-020-1139-5
2. Andreetti C Ibrahim M Gagliardi A Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early-stage large-cell neuroendocrine carcinoma Thorac Cancer 2022 13 7 900 12 10.1111/1759-7714.14287 35170859
Andreetti C, Ibrahim M, Gagliardi A, et al. Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early-stage large-cell neuroendocrine carcinoma. Thorac Cancer. 2022;13(7):900–12.35170859 10.1111/1759-7714.14287
3. Fiorelli A Forte S Natale G Santini M Fang W Handling benign interlobar lymphadenopathy during thoracoscopic lobectomy Thorac Cancer 2021 12 9 1489 92 10.1111/1759-7714.13949 33811459
Fiorelli A, Forte S, Natale G, Santini M, Fang W. Handling benign interlobar lymphadenopathy during thoracoscopic lobectomy. Thorac Cancer. 2021;12(9):1489–92.33811459 10.1111/1759-7714.13949
4. Xia S Wu W Yu L Ma L Chen S Wang H Thrombocytosis predicts poor prognosis of Asian patients with colorectal cancer: a systematic review and meta-analysis Med (Baltim) 2022 101 35 e30275 10.1097/MD.0000000000030275
Xia S, Wu W, Yu L, Ma L, Chen S, Wang H. Thrombocytosis predicts poor prognosis of Asian patients with colorectal cancer: a systematic review and meta-analysis. Med (Baltim). 2022;101(35):e30275.10.1097/MD.0000000000030275
5. Sandfeld-Paulsen B Aggerholm-Pedersen N Winther-Larsen A Pretreatment Platelet Count is a prognostic marker in Lung Cancer: a Danish Registry-based Cohort Study Clin Lung Cancer 2023 24 2 175 83 10.1016/j.cllc.2022.12.012 36646586
Sandfeld-Paulsen B, Aggerholm-Pedersen N, Winther-Larsen A. Pretreatment Platelet Count is a prognostic marker in Lung Cancer: a Danish Registry-based Cohort Study. Clin Lung Cancer. 2023;24(2):175–83.36646586 10.1016/j.cllc.2022.12.012
6. Edahiro Y Kurokawa Y Morishita S Yamamoto T Araki M Komatsu N Causes of thrombocytosis: a single-center Retrospective Study of 1,202 patients Intern Med 2022 61 22 3323 8 10.2169/internalmedicine.9282-21 36385045
Edahiro Y, Kurokawa Y, Morishita S, Yamamoto T, Araki M, Komatsu N. Causes of thrombocytosis: a single-center Retrospective Study of 1,202 patients. Intern Med. 2022;61(22):3323–8. 10.2169/internalmedicine.9282-21. Epub 2022 Nov 15.36385045 10.2169/internalmedicine.9282-21
7. Yu Y Qian L Cui J Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients Mol Clin Oncol 2017 7 3 498 506 10.3892/mco.2017.1342 28811903
Yu Y, Qian L, Cui J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: a meta-analysis of 7,219 patients. Mol Clin Oncol. 2017;7(3):498–506.28811903 10.3892/mco.2017.1342
8. Lim JU Yeo CD Kang HS Park CK Kim JS Kim JW Kim SJ Lee SH Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion PLoS ONE 2018 13 7 e0200341 10.1371/journal.pone.0200341 30005083
Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW, Kim SJ, Lee SH. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. PLoS ONE. 2018;13(7):e0200341.30005083 10.1371/journal.pone.0200341
9. Zhou K Cao J Lin H Liang L Shen Z Wang L Peng Z Mei J Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: a systematic review and meta-analysis Front Oncol 2022 12 962173 10.3389/fonc.2022.962173 36059629
Zhou K, Cao J, Lin H, Liang L, Shen Z, Wang L, Peng Z, Mei J. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: a systematic review and meta-analysis. Front Oncol. 2022;12:962173.36059629 10.3389/fonc.2022.962173
10. Keit E Coutu B Zhen W Zhang C Lin C Bennion N Ganti AK Ernani V Baine M Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer Ann Transl Med 2021 9 3 227 10.21037/atm-20-6710 33708854
Keit E, Coutu B, Zhen W, Zhang C, Lin C, Bennion N, Ganti AK, Ernani V, Baine M. Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer. Ann Transl Med. 2021;9(3):227.33708854 10.21037/atm-20-6710
11. Ma Y Li G Yu M Sun X Nian J Gao Y Li X Ding T Wang X Prognostic significance of thrombocytosis in lung cancer: a systematic review and meta-analysis Platelets 2021 32 7 919 27 10.1080/09537104.2020.1810653 32892682
Ma Y, Li G, Yu M, Sun X, Nian J, Gao Y, Li X, Ding T, Wang X. Prognostic significance of thrombocytosis in lung cancer: a systematic review and meta-analysis. Platelets. 2021;32(7):919–27.32892682 10.1080/09537104.2020.1810653
12. Geranpayehvaghei M Dabirmanesh B Khaledi M Cancer-associated-platelet-inspired nanomedicines for cancer therapy Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021 13 5 e1702 10.1002/wnan.1702 33538125
Geranpayehvaghei M, Dabirmanesh B, Khaledi M, et al. Cancer-associated-platelet-inspired nanomedicines for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(5):e1702.33538125 10.1002/wnan.1702
13. Wojtukiewicz MZ Sierko E Hempel D Tucker SC Honn KV Platelets and cancer angiogenesis nexus Cancer Metastasis Rev 2017 36 2 249 62 10.1007/s10555-017-9673-1 28681240
Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn KV. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev. 2017;36(2):249–62.28681240 10.1007/s10555-017-9673-1
14. Messina G Bove M Noro A Opromolla G Natale G Leone F Di Filippo V Leonardi B Martone M Pirozzi M Caterino M Facchini S Zotta A Vicidomini G Santini M Fiorelli A Corte Carminia D Ciardiello F Fasano M Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign J Cardiothorac Surg 2022 17 1 103 10.1186/s13019-022-01844-4 35509050
Messina G, Bove M, Noro A, Opromolla G, Natale G, Leone F, Di Filippo V, Leonardi B, Martone M, Pirozzi M, Caterino M, Facchini S, Zotta A, Vicidomini G, Santini M, Fiorelli A, Corte Carminia D, Ciardiello F, Fasano M. Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign. J Cardiothorac Surg. 2022;17(1):103.35509050 10.1186/s13019-022-01844-4
15. Josa V Krzystanek M Eklund AC Salamon F Zarand A Szallasi Z Baranyai Z Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer Int J Surg 2015 18 1 6 10.1016/j.ijsu.2015.03.005 25843227
Josa V, Krzystanek M, Eklund AC, Salamon F, Zarand A, Szallasi Z, Baranyai Z. Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer. Int J Surg. 2015;18:1–6.25843227 10.1016/j.ijsu.2015.03.005
16. Milojevic B Janicic A Grozdic Milojevic I Prognostic impact of preoperative thrombocytosis on recurrence-free survival in patients with Upper Tract Urothelial Carcinoma Ann Surg Oncol 2024 31 4 2538 44 10.1245/s10434-023-14844-y 38190056
Milojevic B, Janicic A, Grozdic Milojevic I, et al. Prognostic impact of preoperative thrombocytosis on recurrence-free survival in patients with Upper Tract Urothelial Carcinoma. Ann Surg Oncol. 2024;31(4):2538–44.38190056 10.1245/s10434-023-14844-y
17. Holleran TJ Napolitano MA Duggan JP Peters AS Amdur RL Antevil JL Trachiotis GD Predictors of 30-Day Pulmonary complications after Video-assisted thoracoscopic surgery lobectomy Thorac Cardiovasc Surg 2023 71 4 327 35 10.1055/s-0042-1748025 35785811
Holleran TJ, Napolitano MA, Duggan JP, Peters AS, Amdur RL, Antevil JL, Trachiotis GD. Predictors of 30-Day Pulmonary complications after Video-assisted thoracoscopic surgery lobectomy. Thorac Cardiovasc Surg. 2023;71(4):327–35.35785811 10.1055/s-0042-1748025
18. Rashid A Zeng C Motta-Ribeiro G Dillon ST Libermann TA Lessa MA Bagchi A Hutchinson J Vidal Melo MF Proteomics of lung tissue reveals differences in inflammation and alveolar-capillary barrier response between atelectasis and aerated regions Sci Rep 2022 12 1 7065 10.1038/s41598-022-11045-7 35487970
Rashid A, Zeng C, Motta-Ribeiro G, Dillon ST, Libermann TA, Lessa MA, Bagchi A, Hutchinson J, Vidal Melo MF. Proteomics of lung tissue reveals differences in inflammation and alveolar-capillary barrier response between atelectasis and aerated regions. Sci Rep. 2022;12(1):7065.35487970 10.1038/s41598-022-11045-7
19. Fiorelli A Cascone R Carlucci A Natale G Freda C Bove M Messina G Liguori G Santini M Uniportal thoracoscopic surgical management using a suture traction for primary pneumothorax Asian Cardiovasc Thorac Ann 2021 29 3 195 202 10.1177/0218492320974184 33183063
Fiorelli A, Cascone R, Carlucci A, Natale G, Freda C, Bove M, Messina G, Liguori G, Santini M. Uniportal thoracoscopic surgical management using a suture traction for primary pneumothorax. Asian Cardiovasc Thorac Ann. 2021;29(3):195–202.33183063 10.1177/0218492320974184
20. De Waele M Agzarian J Hanna WC Schieman C Finley CJ Macri J Schneider L Schnurr T Farrokhyar F Radford K Nair P Shargall Y Does the usage of digital chest drainage systems reduce pleural inflammation and volume of pleural effusion following oncologic pulmonary resection? - a prospective randomized trial J Thorac Dis 2017 9 6 1598 606 10.21037/jtd.2017.05.78 28740674
De Waele M, Agzarian J, Hanna WC, Schieman C, Finley CJ, Macri J, Schneider L, Schnurr T, Farrokhyar F, Radford K, Nair P, Shargall Y. Does the usage of digital chest drainage systems reduce pleural inflammation and volume of pleural effusion following oncologic pulmonary resection? - a prospective randomized trial. J Thorac Dis. 2017;9(6):1598–606.28740674 10.21037/jtd.2017.05.78
21. Fiorelli A Natale G Freda C Cascone R Carlucci A Costanzo S Ferrara V Santini M Montgomery T-tube for management of tracheomalacia: impact on voice-related quality of life Clin Respir J 2020 14 1 40 6 10.1111/crj.13098 31622032
Fiorelli A, Natale G, Freda C, Cascone R, Carlucci A, Costanzo S, Ferrara V, Santini M. Montgomery T-tube for management of tracheomalacia: impact on voice-related quality of life. Clin Respir J. 2020;14(1):40–6.31622032 10.1111/crj.13098
22. Zhang X Ran Y Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis Int J Clin Exp Med 2015 8 4 5379 87 26131114
Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(4):5379–87.26131114
23. Lee S Eo W Jeon H Park S Chae J Prognostic significance of host-related biomarkers for survival in patients with Advanced Non-small Cell Lung Cancer J Cancer 2017 8 15 2974 83 10.7150/jca.20866 28928889
Lee S, Eo W, Jeon H, Park S, Chae J. Prognostic significance of host-related biomarkers for survival in patients with Advanced Non-small Cell Lung Cancer. J Cancer. 2017;8(15):2974–83.28928889 10.7150/jca.20866
24. Liu C Zhang H Qi Q Zhang B Yue D Wang C The preoperative platelet distribution width: a predictive factor of the prognosis in patients with non-small cell lung cancer Thorac Cancer 2020 11 4 918 27 10.1111/1759-7714.13340 32061027
Liu C, Zhang H, Qi Q, Zhang B, Yue D, Wang C. The preoperative platelet distribution width: a predictive factor of the prognosis in patients with non-small cell lung cancer. Thorac Cancer. 2020;11(4):918–27.32061027 10.1111/1759-7714.13340
25. Skorek P Stępień K Fila M Hauer J Kużdżał J Preoperative thrombocytosis in surgically treated patients with non-small cell lung cancer Pol Arch Intern Med 2018 128 9 512 7 30057382
Skorek P, Stępień K, Fila M, Hauer J, Kużdżał J. Preoperative thrombocytosis in surgically treated patients with non-small cell lung cancer. Pol Arch Intern Med. 2018;128(9):512–7.30057382
26. Li M Zhao S Lopez G Secor A Das P Surya N Grogan M Patel S Chakravarthy K Miah A Spakowicz D Tinoco G Li Z Wei L He K Bertino E Alahmadi A Memmott R Kaufman J Shields PG Carbone DP Presley CJ Otterson GA Owen DH Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy Cancer Immunol Immunother 2023 72 7 2067 74 10.1007/s00262-023-03392-9 36795122
Li M, Zhao S, Lopez G, Secor A, Das P, Surya N, Grogan M, Patel S, Chakravarthy K, Miah A, Spakowicz D, Tinoco G, Li Z, Wei L, He K, Bertino E, Alahmadi A, Memmott R, Kaufman J, Shields PG, Carbone DP, Presley CJ, Otterson GA, Owen DH. Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy. Cancer Immunol Immunother. 2023;72(7):2067–74.36795122 10.1007/s00262-023-03392-9
27. Saha B Khatun N Azim N Islam SA Proteek MF Islam MR Begum FA Biddut MA Khan MK Islam MR Platelet count as a prognostic factor in Stage IV Non-small Cell Lung Cancer Mymensingh Med J 2022 31 4 937 46 36189536
Saha B, Khatun N, Azim N, Islam SA, Proteek MF, Islam MR, Begum FA, Biddut MA, Khan MK, Islam MR. Platelet count as a prognostic factor in Stage IV Non-small Cell Lung Cancer. Mymensingh Med J. 2022;31(4):937–46.36189536
28. Maráz A Furák J Varga Z Kahán Z Tiszlavicz L Hideghéty K Thrombocytosis has a negative prognostic value in lung cancer Anticancer Res 2013 33 4 1725 9 23564823
Maráz A, Furák J, Varga Z, Kahán Z, Tiszlavicz L, Hideghéty K. Thrombocytosis has a negative prognostic value in lung cancer. Anticancer Res. 2013;33(4):1725–9.23564823
29. Scharf RE Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment Hamostaseologie 2016 36 4 241 60 10.5482/HAMO-16-06-0016 27414763
Scharf RE. Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment. Hamostaseologie. 2016;36(4):241–60.27414763 10.5482/HAMO-16-06-0016
30. Madaan GB, Jairajpuri ZS, Hajini FF, Jetley S. Postoperative thrombocytosis: an unusual case report. Int J Appl Basic Med Res. 2015 Sep-Dec;5(3):225–7.
31. Mohamud M Osborne L Jones HG Ahmed A Beynon J Harris DA Evans M Davies M Khot U Chandrasekaran TV Thrombocytosis as a marker for postoperative complications in colorectal surgery Gastroenterol Res Pract 2018 2018 1978639 10.1155/2018/1978639 30224916
Mohamud M, Osborne L, Jones HG, Ahmed A, Beynon J, Harris DA, Evans M, Davies M, Khot U, Chandrasekaran TV. Thrombocytosis as a marker for postoperative complications in colorectal surgery. Gastroenterol Res Pract. 2018;2018:1978639.30224916 10.1155/2018/1978639
32. Messina G Bove M Natale G Di Filippo V Opromolla G Rainone A Leonardi B Martone M Fiorelli A Vicidomini G Santini M Ronchi A Massimilla E Della Corte CM Pirozzi M Caterino M Ciardiello F Fasano M Diagnosis of malignant pleural disease: Ultrasound as a detective probe Thorac Cancer 2023 14 3 223 30 10.1111/1759-7714.14735 36415167
Messina G, Bove M, Natale G, Di Filippo V, Opromolla G, Rainone A, Leonardi B, Martone M, Fiorelli A, Vicidomini G, Santini M, Ronchi A, Massimilla E, Della Corte CM, Pirozzi M, Caterino M, Ciardiello F, Fasano M. Diagnosis of malignant pleural disease: Ultrasound as a detective probe. Thorac Cancer. 2023;14(3):223–30.36415167 10.1111/1759-7714.14735
33. Chen Y Zhong H Zhao Y Luo X Gao W Role of platelet biomarkers in inflammatory response Biomark Res 2020 8 28 10.1186/s40364-020-00207-2 32774856
Chen Y, Zhong H, Zhao Y, Luo X, Gao W. Role of platelet biomarkers in inflammatory response. Biomark Res. 2020;8:28.32774856 10.1186/s40364-020-00207-2
